IMmunoPhenotyping Assessment of a Covid-19 Cohort (IMPACC): Clinical Site

PROJECT SUMMARY:From a cluster of respiratory illnesses in Wuhan, China, to a worldwide pandemic, the world has learned of anovel coronavirus (SARS-CoV-2) but little is known about the pathogenesis that leads to the disease termed"COVID". Patients with SARS-CoV-2 infection range from asymptomatic, mild, moderate, to severe infections,resulting in ICU hospitalization and even death. In the US alone, there is a prediction of ~100,000 - 240,000deaths from SARS-CoV-2 infections. There is an urgent need to immunophenotype patients with COVID todefine biomarkers of disease severity and outcome to inform new interventions to prevent or treat this deadlydisease. Key to characterizing the human immune response to SARS-CoV-2, is recruitment , enrollment andretention of a cohort of study participants with COVID. To this end, we will employ best practices in clinicalresearch to pursue three Specific Aims (SAs). In SA1, we will recruit and enroll a well-defined cohort of adultswith SARS-CoV-2 (COVID-19); in SA2, we will obtain and store biosamples from patients in this COVID-19cohort in support the NIAID immunophenotyping effort and in SA3 we will partner with the Clinical & DataCoordinating Center (CDCC) to provide clinical data from this COVID-19 cohort to ensure these samples arehighly annotated with key clinical data.Overall, successful pursuit of these SAs will provide well defined clinical samples and high qualityclinical data to support the NIAID COVID immunophenotyping effort.